Vimarsana
Biggest News Aggregation in the World

Page 11 - Pascal Touchon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pascal Touchon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pascal Touchon Today - Breaking & Trending Today

Nisa Investment Advisors LLC Buys 5,810 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Vimarsana News

Nisa Investment Advisors LLC Buys 5,810 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Nisa Investment Advisors LLC raised its stake in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 893.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 6,460 shares of the biotechnology company’s stock after purchasing an additional 5,810 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Atara Biotherapeutics were worth […]

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational - Vimarsana News

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational

Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel®ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023Cash Runway Extended into Q2 2024THOUSAND OAKS, Calif.--(BUSINESS WIRE)--$ATRA #CART--Atara Biotherapeut...

Pierre Fabre to lead commercialisation of EBVALLO® - Vimarsana News

Pierre Fabre to lead commercialisation of EBVALLO®

Following transfer of the EC marketing authorisation from Atara, Pierre Fabre will lead commercialisation of EBVALLO® in Europe.

Atara Biotherapeutics, Inc.: Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel) - Vimarsana News

Atara Biotherapeutics, Inc.: Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel)

Pierre Fabre to Lead Launch and Commercialization Activities for EBVALLO In Europe Following Transfer of European Commission Marketing Authorization from Atara Biotherapeutics EBVALLO is the

Creative Planning Buys 6,390 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Vimarsana News

Creative Planning Buys 6,390 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Creative Planning grew its stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 10.5% in the 3rd quarter, Holdings Channel reports. The firm owned 67,118 shares of the biotechnology company’s stock after purchasing an additional 6,390 shares during the period. Creative Planning’s holdings in Atara Biotherapeutics were worth $254,000 at the end of the […]